GBP Announces Finalists for 2007 Deal of Year Honors

Dec 21, 2006, 00:00 ET from Georgia Biomedical Partnership

    ATLANTA, Dec. 21 /PRNewswire-USNewswire/ -- Georgia's life sciences
 industry achieved significant milestones in 2006 in the negotiation of
 major business deals, such as financings, collaborations and acquisitions.
 The Georgia Biomedical Partnership (GBP) has identified 11 finalists in
 four categories for the annual Deal of the Year awards. Winners will be
 named at the GBP's Annual Awards Dinner January 12, 2007 at the
 Intercontinental Buckhead Hotel in Atlanta.
     The categories are Early Stage Financing; Strategic Transaction (Large
 Companies); Strategic Transaction (Small Companies); and Public Sector.
     In the Public Sector, the winner already has been declared. Emory
 University, Georgia Institute of Technology, and Medical College of
 Georgia, will be recognized for a $10 million National Institutes of Health
 grant to create a Nanomedicine Development Center. The center is an
 international partnership also involving California Institute of
 Technology, Cold Spring Harbor Laboratory, New York University School of
 Medicine, Massachusetts Institute of Technology and the German Cancer
 Research Center.
     Following are finalists in the other three categories.
     Early Stage Financing: Biofisica, for a $5 million Series A round;
 CardioMEMS, for a $22.6 million Series D round; Insectigen, for a $1.2
 million sale of convertible notes; and Metastatix, for a $3.6 million
 Series A round.
     Strategic Transaction (Large Company): AtheroGenics, for its
 partnership with AstraZeneca worth up to $1 billion; Serologicals, for its
 acquisition by Millipore for $1.4 billion; Solvay Pharmaceuticals, for a
 $298 million federal grant for development of cell-based vaccines; and UCB
 for its estimated $5.6 billion acquisition of Schwarz Pharma.
     Strategic Transaction (Small Company): GeoVax Labs, for its $2 million
 reverse merger with Dauphin Technology, enabling GeoVax to become a
 publicly traded company; and Theragenics, for its $32 million acquisition
 of Galt Medical Corp.
     The GBP's top annual award is the Biomedical Industry Growth Award,
 recognizing individuals from the public and private sectors for outstanding
 contributions to life sciences industry growth. The 2007 winners are Don P.
 Giddens, Ph.D., Dean of Georgia Institute of Technology's College of
 Engineering (public sector), and Eric Tomlinson, DSc, Ph.D., President and
 CEO of Altea Therapeutics (private sector).
     Also recognized will be an Emerging Leader of the Year and the
 Biomedical Community Award winners. To register for the GBP's Annual Awards
 Dinner, go to www.gabio.org
     About Georgia Biomedical Partnership
     The Georgia Biomedical Partnership (GBP), founded in 1989, represents
 more than 270 pharmaceutical, biotech and medical device companies,
 universities, research institutes, government groups and other business
 organizations involved in the research and development of products that
 improve the health and quality of life of people worldwide. For more
 information visit www.gabio.org
 
 

SOURCE Georgia Biomedical Partnership
    ATLANTA, Dec. 21 /PRNewswire-USNewswire/ -- Georgia's life sciences
 industry achieved significant milestones in 2006 in the negotiation of
 major business deals, such as financings, collaborations and acquisitions.
 The Georgia Biomedical Partnership (GBP) has identified 11 finalists in
 four categories for the annual Deal of the Year awards. Winners will be
 named at the GBP's Annual Awards Dinner January 12, 2007 at the
 Intercontinental Buckhead Hotel in Atlanta.
     The categories are Early Stage Financing; Strategic Transaction (Large
 Companies); Strategic Transaction (Small Companies); and Public Sector.
     In the Public Sector, the winner already has been declared. Emory
 University, Georgia Institute of Technology, and Medical College of
 Georgia, will be recognized for a $10 million National Institutes of Health
 grant to create a Nanomedicine Development Center. The center is an
 international partnership also involving California Institute of
 Technology, Cold Spring Harbor Laboratory, New York University School of
 Medicine, Massachusetts Institute of Technology and the German Cancer
 Research Center.
     Following are finalists in the other three categories.
     Early Stage Financing: Biofisica, for a $5 million Series A round;
 CardioMEMS, for a $22.6 million Series D round; Insectigen, for a $1.2
 million sale of convertible notes; and Metastatix, for a $3.6 million
 Series A round.
     Strategic Transaction (Large Company): AtheroGenics, for its
 partnership with AstraZeneca worth up to $1 billion; Serologicals, for its
 acquisition by Millipore for $1.4 billion; Solvay Pharmaceuticals, for a
 $298 million federal grant for development of cell-based vaccines; and UCB
 for its estimated $5.6 billion acquisition of Schwarz Pharma.
     Strategic Transaction (Small Company): GeoVax Labs, for its $2 million
 reverse merger with Dauphin Technology, enabling GeoVax to become a
 publicly traded company; and Theragenics, for its $32 million acquisition
 of Galt Medical Corp.
     The GBP's top annual award is the Biomedical Industry Growth Award,
 recognizing individuals from the public and private sectors for outstanding
 contributions to life sciences industry growth. The 2007 winners are Don P.
 Giddens, Ph.D., Dean of Georgia Institute of Technology's College of
 Engineering (public sector), and Eric Tomlinson, DSc, Ph.D., President and
 CEO of Altea Therapeutics (private sector).
     Also recognized will be an Emerging Leader of the Year and the
 Biomedical Community Award winners. To register for the GBP's Annual Awards
 Dinner, go to www.gabio.org
     About Georgia Biomedical Partnership
     The Georgia Biomedical Partnership (GBP), founded in 1989, represents
 more than 270 pharmaceutical, biotech and medical device companies,
 universities, research institutes, government groups and other business
 organizations involved in the research and development of products that
 improve the health and quality of life of people worldwide. For more
 information visit www.gabio.org
 
 SOURCE Georgia Biomedical Partnership